EC
PTCT icon

EntryPoint Capital’s PTC Therapeutics PTCT Stock Holding History

EntryPoint Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$317K Buy
+4,650
New +$329K 0.09% 443
2025
Q4 		– Sell
-7,384
Closed -$453K – 822
2025
Q3 		$453K Buy
7,384
+574
+8% +$29.9K 0.18% 203
2025
Q2 		$333K Buy
+6,810
New +$323K 0.17% 233
2024
Q4 		– Sell
-8,836
Closed -$328K – 920
2024
Q3 		$328K Buy
8,836
+4,781
+118% +$160K 0.19% 211
2024
Q2 		$124K Buy
4,055
+1,794
+79% +$58.1K 0.18% 213
2024
Q1 		$65.8K Sell
2,261
-3,401
-60% -$95.3K 0.06% 625
2023
Q4 		$156K Buy
+5,662
New +$129K 0.15% 174

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EntryPoint Capital's PTCT Position: Q1 2026 in Review

EntryPoint Capital opened a new position in PTC Therapeutics (PTCT) in Q1 2026: 4,650 shares worth $317K. The stake represents 0.09% of the portfolio and ranks #443 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in PTCT as recently as Q3 2025.

EntryPoint Capital first reported a position in PTCT in Q4 2023 and has held it in 7 quarters since. The position peaked at $453K in Q3 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • EntryPoint Capital held 4,650 shares of PTC Therapeutics worth $317K as of Q1 2026.
  • PTC Therapeutics was a new EntryPoint Capital position in Q1 2026.
  • PTC Therapeutics made up 0.09% of EntryPoint Capital's portfolio in Q1 2026, its #443 holding.
  • EntryPoint Capital first reported a position in PTC Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • EntryPoint Capital's PTC Therapeutics position peaked at $453K in Q3 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.